{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:42:04Z","timestamp":1788280924714,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG24449"],"award-info":[{"award-number":["IG24449"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06942-0","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T16:49:18Z","timestamp":1755190158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax"],"prefix":"10.1186","volume":"23","author":[{"given":"Ilenia","family":"Valentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Gallo Cantafio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Torcasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Murfone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ganino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cuscino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Tallarigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mesuraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"6942_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024;5:1267\u201384.","journal-title":"Nat Cancer"},{"key":"6942_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","volume":"9","author":"Y Zong","year":"2024","unstructured":"Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:124.","journal-title":"Signal Transduct Target Ther"},{"key":"6942_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1000106","author":"R Nair","year":"2022","unstructured":"Nair R, Gupta P, Shanmugam M. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1000106.","journal-title":"Front Oncol"},{"key":"6942_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604143","author":"A Barbato","year":"2020","unstructured":"Barbato A, Scandura G, Puglisi F, Cambria D, La Spina E, Palumbo GA, et al. Mitochondrial bioenergetics at the onset of drug resistance in hematological malignancies: an overview. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.604143.","journal-title":"Front Oncol"},{"key":"6942_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/cancers13061235","volume":"13","author":"T Paradzik","year":"2021","unstructured":"Paradzik T, Bandini C, Mereu E, Labrador M, Taiana E, Amodio N, et al. The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers (Basel). 2021;13:1235.","journal-title":"Cancers (Basel)"},{"key":"6942_CR6","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3390\/cancers14133271","volume":"14","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, Da Vi\u00e0 MC, Bolli N, Steinbrunn T. The route of the malignant plasma cell in its survival niche: exploring \u201cmultiple myelomas.\u201d Cancers (Basel). 2022;14:3271.","journal-title":"Cancers (Basel)"},{"key":"6942_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12967-024-05848-7","volume":"23","author":"X Wang","year":"2025","unstructured":"Wang X, Cheng L, Liu A, Liu L, Gong L, Shen G. Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis. J Transl Med. 2025;23:163.","journal-title":"J Transl Med"},{"key":"6942_CR8","first-page":"16","volume":"9","author":"ME Gallo Cantafio","year":"2023","unstructured":"Gallo Cantafio ME, Torcasio R, Viglietto G, Amodio N. Non-coding RNA-dependent regulation of mitochondrial dynamics in cancer pathophysiology. Noncoding RNA. 2023;9:16.","journal-title":"Noncoding RNA"},{"key":"6942_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12967-023-04845-6","volume":"22","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhang X, Liu H, Yang C, Yu J, Zhao W, et al. MTFR2-dependent mitochondrial fission promotes HCC progression. J Transl Med. 2024;22:73.","journal-title":"J Transl Med"},{"key":"6942_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12967-023-04188-2","volume":"21","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yang B, Tu C, Ping Y, Chen S, Wu T, et al. Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells. J Transl Med. 2023;21:328.","journal-title":"J Transl Med"},{"key":"6942_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1186\/s12967-024-05770-y","volume":"22","author":"X Cui","year":"2024","unstructured":"Cui X, Xu J, Jia X. Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer. J Transl Med. 2024;22:968.","journal-title":"J Transl Med"},{"key":"6942_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12967-023-04498-5","volume":"21","author":"C Rocca","year":"2023","unstructured":"Rocca C, Soda T, De Francesco EM, Fiorillo M, Moccia F, Viglietto G, et al. Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer. J Transl Med. 2023;21:635.","journal-title":"J Transl Med"},{"key":"6942_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12967-024-05013-0","volume":"22","author":"R Torcasio","year":"2024","unstructured":"Torcasio R, Gallo Cantafio ME, Veneziano C, De Marco C, Ganino L, Valentino I, et al. Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity. J Transl Med. 2024;22:208.","journal-title":"J Transl Med"},{"key":"6942_CR14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287526","author":"MEG Cantafio","year":"2025","unstructured":"Cantafio MEG, Valentino I, Torcasio R, Ganino L, Veneziano C, Murfone P, et al. Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.287526.","journal-title":"Haematologica"},{"key":"6942_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-025-01210-2","volume":"15","author":"AG Solimando","year":"2025","unstructured":"Solimando AG, Di Palma F, Desantis V, Vacca A, Svelto M, Pisani F. Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma. Blood Cancer J. 2025;15:3.","journal-title":"Blood Cancer J"},{"key":"6942_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s10555-024-10201-x","volume":"43","author":"A Behera","year":"2024","unstructured":"Behera A, Sachan D, Barik GK, Reddy ABM. Role of MARCH E3 ubiquitin ligases in cancer development. Cancer Metastasis Rev. 2024;43:1257\u201377.","journal-title":"Cancer Metastasis Rev"},{"key":"6942_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1186\/s12967-024-05565-1","volume":"22","author":"Y Wu","year":"2024","unstructured":"Wu Y, Chen Y, Tian X, Shao G, Lin Q, Sun A. Ubiquitination regulates autophagy in cancer: simple modifications, promising targets. J Transl Med. 2024;22:985.","journal-title":"J Transl Med"},{"key":"6942_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41375-023-01879-z","volume":"37","author":"F Nakao","year":"2023","unstructured":"Nakao F, Setoguchi K, Semba Y, Yamauchi T, Nogami J, Sasaki K, et al. Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance. Leukemia. 2023;37:1028\u201338.","journal-title":"Leukemia"},{"key":"6942_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2023-184392","volume":"142","author":"TE Lew","year":"2023","unstructured":"Lew TE, Van Delft M, Riffkin C, Angela G, White C, Yuan Y, et al. Depletion of the mitochondrial E3 ligase MARCH5 induces synthetic lethality to BCL2 inhibitor (venetoclax) therapy in cell lines representative of diverse blood cancers. Blood. 2023;142:415\u2013415.","journal-title":"Blood"},{"key":"6942_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou\u2013Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"6942_CR21","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3390\/cells12182226","volume":"12","author":"ME Gallo Cantafio","year":"2023","unstructured":"Gallo Cantafio ME, Torcasio R, Scionti F, Mesuraca M, Ronchetti D, Pistoni M, et al. GPER1 activation exerts anti-tumor activity in multiple myeloma. Cells. 2023;12:2226.","journal-title":"Cells"},{"key":"6942_CR22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114\u201320.","journal-title":"Bioinformatics"},{"key":"6942_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"issue":"4","key":"6942_CR24","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.bneo.2024.100046","volume":"1","author":"H Bashiri","year":"2024","unstructured":"Bashiri H, Khalilnezhad A, Totani H, Yeong J, Chung T-H, Wee F, et al. Deciphering MARCH5\u2019s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling. Blood Neoplasia. 2024;1(4):100046.","journal-title":"Blood Neoplasia"},{"issue":"16","key":"6942_CR25","doi-asserted-by":"publisher","first-page":"e126915","DOI":"10.1172\/jci.insight.126915","volume":"4","author":"M Yu","year":"2019","unstructured":"Yu M, Nguyen ND, Huang Y, Lin D, Fujimoto TN, Molkentine JM, et al. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019;4(16):e126915.","journal-title":"JCI Insight"},{"key":"6942_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1535-7163.MCT-20-0567","volume":"20","author":"R Jin","year":"2021","unstructured":"Jin R, Liu B, Liu X, Fan Y, Peng W, Huang C, et al. Leflunomide suppresses the growth of LKB1-inactivated tumors in the immune-competent host and attenuates distant cancer metastasis. Mol Cancer Ther. 2021;20:274\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6942_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s41467-020-15051-z","volume":"11","author":"R Bajpai","year":"2020","unstructured":"Bajpai R, Sharma A, Achreja A, Edgar CL, Wei C, Siddiqa AA, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun [Internet]. 2020;11(1):1228.","journal-title":"Nat Commun [Internet]"},{"key":"6942_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-025-01699-x","volume":"18","author":"V Desantis","year":"2025","unstructured":"Desantis V, Andriano A, D\u00fcking T, Hartwig O, Ingravallo G, Biondo M, et al. Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease. J Hematol Oncol. 2025;18:47.","journal-title":"J Hematol Oncol"},{"key":"6942_CR29","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","volume":"105","author":"A Gulla","year":"2020","unstructured":"Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105:2358\u201367.","journal-title":"Haematologica"},{"key":"6942_CR30","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.3390\/cancers13092127","volume":"13","author":"E Taiana","year":"2021","unstructured":"Taiana E, Gallo Cantafio ME, Favasuli VK, Bandini C, Viglietto G, Piva R, et al. Genomic instability in multiple myeloma: a \u201cnon-coding RNA\u201d perspective. Cancers (Basel). 2021;13:2127.","journal-title":"Cancers (Basel)"},{"key":"6942_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","volume":"25","author":"MC Da Vi\u00e0","year":"2020","unstructured":"Da Vi\u00e0 MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, et al. CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement. Oncologist. 2020;25:112\u20138.","journal-title":"Oncologist"},{"key":"6942_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/jcm8070997","volume":"8","author":"AG Solimando","year":"2019","unstructured":"Solimando AG, Da Vi\u00e0 MC, Cicco S, Leone P, Di Lernia G, Giannico D, et al. High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. J Clin Med. 2019;8:997.","journal-title":"J Clin Med"},{"key":"6942_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12967-023-04141-3","volume":"21","author":"X Xu","year":"2023","unstructured":"Xu X, Wang X, Chen Q, Zheng A, Li D, Meng Z, et al. Sp1 promotes tumour progression by remodelling the mitochondrial network in cervical cancer. J Transl Med. 2023;21:307.","journal-title":"J Transl Med"},{"key":"6942_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12967-023-04200-9","volume":"21","author":"F Du","year":"2023","unstructured":"Du F, Yang L, Liu J, Wang J, Fan L, Duangmano S, et al. The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. J Transl Med. 2023;21:345.","journal-title":"J Transl Med"},{"key":"6942_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-022-03851-4","volume":"21","author":"P Huang","year":"2023","unstructured":"Huang P, Fan X, Yu H, Zhang K, Li H, Wang Y, et al. Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. J Transl Med. 2023;21:94.","journal-title":"J Transl Med"},{"key":"6942_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1091\/mbc.e16-04-0208","volume":"28","author":"E Cherok","year":"2017","unstructured":"Cherok E, Xu S, Li S, Das S, Meltzer WA, Zalzman M, et al. Novel regulatory roles of Mff and Drp1 in E3 ubiquitin ligase MARCH5\u2013dependent degradation of MiD49 and Mcl1 and control of mitochondrial dynamics. Mol Biol Cell. 2017;28:396\u2013410.","journal-title":"Mol Biol Cell"},{"issue":"12","key":"6942_CR37","doi-asserted-by":"publisher","first-page":"e57496","DOI":"10.15252\/embr.202357496","volume":"24","author":"K Son","year":"2023","unstructured":"Son K, Jeong S, Eom E, Kwon D, Kang S. MARCH5 promotes STING pathway activation by suppressing polymer formation of oxidized STING. EMBO Rep. 2023;24(12):e57496.","journal-title":"EMBO Rep"},{"key":"6942_CR38","doi-asserted-by":"publisher","first-page":"10300","DOI":"10.1074\/jbc.RA118.006302","volume":"294","author":"F Koyano","year":"2019","unstructured":"Koyano F, Yamano K, Kosako H, Tanaka K, Matsuda N. Parkin recruitment to impaired mitochondria for nonselective ubiquitylation is facilitated by MITOL. J Biol Chem. 2019;294:10300\u201314.","journal-title":"J Biol Chem"},{"key":"6942_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15252\/embr.201643309","volume":"18","author":"Z Chen","year":"2017","unstructured":"Chen Z, Liu L, Cheng Q, Li Y, Wu H, Zhang W, et al. Mitochondrial E3 ligase MARCH5 regulates FUNDC1 to fine-tune hypoxic mitophagy. EMBO Rep. 2017;18:495\u2013509.","journal-title":"EMBO Rep"},{"key":"6942_CR40","doi-asserted-by":"publisher","first-page":"105087","DOI":"10.1016\/j.jbc.2023.105087","volume":"299","author":"M Hussain","year":"2023","unstructured":"Hussain M, Mohammed A, Saifi S, Priya S, Sengupta S. Hyperubiquitylation of DNA helicase RECQL4 by E3 ligase MITOL prevents mitochondrial entry and potentiates mitophagy. J Biol Chem. 2023;299:105087.","journal-title":"J Biol Chem"},{"key":"6942_CR41","doi-asserted-by":"publisher","first-page":"e1172","DOI":"10.1038\/cddis.2014.142","volume":"5","author":"Y-Y Park","year":"2014","unstructured":"Park Y-Y, Nguyen OTK, Kang H, Cho H. MARCH5-mediated quality control on acetylated Mfn1 facilitates mitochondrial homeostasis and cell survival. Cell Death Dis. 2014;5:e1172\u2013e1172.","journal-title":"Cell Death Dis"},{"key":"6942_CR42","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/sj.embor.7400790","volume":"7","author":"N Nakamura","year":"2006","unstructured":"Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S. MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology. EMBO Rep. 2006;7:1019\u201322.","journal-title":"EMBO Rep"},{"key":"6942_CR43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s44318-024-00044-1","volume":"43","author":"E Vringer","year":"2024","unstructured":"Vringer E, Heilig R, Riley JS, Black A, Cloix C, Skalka G, et al. Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-\u03baB-mediated inflammatory response. EMBO J. 2024;43:904\u201330.","journal-title":"EMBO J"},{"key":"6942_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1242\/jcs.061481","volume":"123","author":"Y-Y Park","year":"2010","unstructured":"Park Y-Y, Lee S, Karbowski M, Neutzner A, Youle RJ, Cho H. Loss of MARCH5 mitochondrial E3 ubiquitin ligase induces cellular senescence through dynamin-related protein 1 and mitofusin 1. J Cell Sci. 2010;123:619\u201326.","journal-title":"J Cell Sci"},{"key":"6942_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1083\/jcb.200611064","volume":"178","author":"M Karbowski","year":"2007","unstructured":"Karbowski M, Neutzner A, Youle RJ. The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J Cell Biol. 2007;178:71\u201384.","journal-title":"J Cell Biol"},{"key":"6942_CR46","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1016\/j.jid.2021.03.031","volume":"141","author":"H Wang","year":"2021","unstructured":"Wang H, Yi X, Guo S, Wang S, Ma J, Zhao T, et al. The XBP1-MARCH5-MFN2 axis confers endoplasmic reticulum stress resistance by coordinating mitochondrial fission and mitophagy in melanoma. J Invest Dermatol. 2021;141:2932-2943.e12.","journal-title":"J Invest Dermatol"},{"key":"6942_CR47","doi-asserted-by":"publisher","first-page":"15986","DOI":"10.18632\/oncotarget.7558","volume":"7","author":"A Subramanian","year":"2016","unstructured":"Subramanian A, Andronache A, Li Y-C, Wade M. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA. Oncotarget. 2016;7:15986\u20136002.","journal-title":"Oncotarget"},{"key":"6942_CR48","doi-asserted-by":"publisher","first-page":"e1006648","DOI":"10.1371\/journal.ppat.1006648","volume":"13","author":"B-R Yan","year":"2017","unstructured":"Yan B-R, Zhou L, Hu M-M, Li M, Lin H, Yang Y, et al. PKacs attenuate innate antiviral response by phosphorylating VISA and priming it for MARCH5-mediated degradation. Plos Pathog. 2017;13:e1006648.","journal-title":"Plos Pathog"},{"key":"6942_CR49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-20-1851","volume":"12","author":"S Lin","year":"2022","unstructured":"Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2022;12:432\u201349.","journal-title":"Cancer Discov"},{"key":"6942_CR50","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/10428194.2020.1742900","volume":"61","author":"M Rosenzweig","year":"2020","unstructured":"Rosenzweig M, Palmer J, Tsai N-C, Synold T, Wu X, Tao S, et al. Repurposing leflunomide for relapsed\/refractory multiple myeloma: a phase 1 study. Leuk Lymphoma. 2020;61:1669\u201377.","journal-title":"Leuk Lymphoma"},{"key":"6942_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.16483","volume":"189","author":"C Boccon-Gibod","year":"2020","unstructured":"Boccon-Gibod C, Talbot A, Le Bras F, Frenzel L, Royer B, Harel S, et al. Carfilzomib, venetoclax and dexamethasone for relapsed\/refractory multiple myeloma. Br J Haematol. 2020;189:3.","journal-title":"Br J Haematol"},{"key":"6942_CR52","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2021;5:3748\u201359.","journal-title":"Blood Adv"},{"key":"6942_CR53","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"6942_CR54","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho S-J, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39:3602\u201312.","journal-title":"J Clin Oncol"},{"key":"6942_CR55","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401\u20139.","journal-title":"Blood"},{"key":"6942_CR56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","volume":"28","author":"C Touzeau","year":"2014","unstructured":"Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210\u20132.","journal-title":"Leukemia"},{"key":"6942_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood.2023020276","volume":"143","author":"N Leblay","year":"2024","unstructured":"Leblay N, Ahn S, Tilmont R, Poorebrahim M, Maity R, Lee H, et al. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood. 2024;143:42\u201356.","journal-title":"Blood"},{"key":"6942_CR58","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021;137:3604\u201315.","journal-title":"Blood"},{"key":"6942_CR59","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1038\/onc.2015.464","volume":"35","author":"R Bajpai","year":"2016","unstructured":"Bajpai R, Matulis SM, Wei C, Nooka AK, Von Hollen HE, Lonial S, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. 2016;35:3955\u201364.","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1186\/s12967-025-07052-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06942-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T08:03:20Z","timestamp":1762934600000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6942"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06942-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-025-07052-7","URL":"https:\/\/doi.org\/10.1186\/s12967-025-07052-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peripheral blood mononuclear cells (PBMCs) were isolated following informed consent and Institutional Review Board (University of Catanzaro, Catanzaro, Italy) approval (institutional approval: n. 266\/2021). Animal experimentation was carried out at University Magna Graecia of Catanzaro under the Italian MOH authorization n. 887\/2021-PR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"917"}}